晚期结直肠癌抗血管生成靶向治疗研究进展  

Update on Anti-angiogenic Targeted Therapies in Advanced Colorectal Cancer

作　　者：王伟林[1] 闻浩[1] 

机构地区：[1]南京医科大学第二附属医院普外科,南京210011

出　　处：《医学综述》2015年第13期2366-2368,共3页Medical Recapitulate

摘　　要：结直肠癌是最常见的恶性肿瘤之一,靶向治疗在其治疗模式中发挥着重要作用。肿瘤血管生成是肿瘤生长、浸润和转移中的关键环节,针对新生血管的靶向药物在肿瘤综合治疗中扮演越来越重要的角色。目前在临床中被批准用于晚期结直肠癌的抗血管药物主要有贝伐单抗、阿柏西普、瑞格非尼等。该文就抗血管生成靶向药物在晚期结直肠癌靶向治疗中的研究进展进行综述。Colorectal cancer is one of the most common malignant tumors , and targeted therapy plays vital roles in its treatment.As tumor angiogenesis plays a critical role in the process of tumor growth ,invasion and metastasis,drugs targeted angiogenesis have become more and more important in the comprehensive ther-apy of cancer.Three antiangiogenic agents are currently approved in the clinical treatment of advanced color-ectal cancer：bevacizumab,ziv-aflibercep,and regorafenib.Here is to make a review of the progression of anti-angiogenesis drugs in the targeted therapy of advanced colorectal cancer .

关 键 词：晚期结直肠癌 抗血管生成 贝伐单抗 瑞哥非尼 阿柏西普 

分 类 号：R735.34[医药卫生—肿瘤]